Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $47.00

Stoke Therapeutics (NASDAQ:STOK) had its price target boosted by analysts at HC Wainwright from $35.00 to $47.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 382.50% from the company’s previous close.

A number of other research firms have also recently issued reports on STOK. Chardan Capital started coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Stock Performance

NASDAQ STOK traded down $0.94 during trading on Tuesday, hitting $9.74. The stock had a trading volume of 1,405,755 shares, compared to its average volume of 839,443. Stoke Therapeutics has a one year low of $5.14 and a one year high of $17.58. The stock has a 50 day simple moving average of $10.84 and a 200 day simple moving average of $12.40. The stock has a market capitalization of $515.98 million, a price-to-earnings ratio of -4.64 and a beta of 0.95.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of Stoke Therapeutics stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $78,852.60. Following the transaction, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. The trade was a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 13,945 shares of the firm’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $178,217.10. Following the completion of the sale, the insider now owns 47,332 shares in the company, valued at $604,902.96. This represents a 22.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 62,849 shares of company stock valued at $809,421. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently made changes to their positions in the business. Barclays PLC increased its position in Stoke Therapeutics by 145.3% during the 3rd quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after buying an additional 47,239 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock worth $10,705,000 after acquiring an additional 76,661 shares during the last quarter. State Street Corp increased its holdings in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after acquiring an additional 137,145 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after purchasing an additional 71,647 shares during the last quarter. Finally, RTW Investments LP boosted its stake in Stoke Therapeutics by 10.1% in the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock worth $57,177,000 after purchasing an additional 427,447 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.